Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARM 210

Next Previous
Search
Drug Profile

ARM 210

Alternative Names: ARM-210; S-48168

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARMGO Pharma
  • Developer ARMGO Pharma; National Institute of Neurological Disorders and Stroke; Servier
  • Class Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital structural myopathies; Polymorphic catecholergic ventricular tachycardia; Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Polymorphic catecholergic ventricular tachycardia
  • No development reported Congenital structural myopathies; Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Sarcopenia; X-linked bulbo-spinal atrophy

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Congenital structural myopathies(In the elderly, In adults) in USA (PO, Pill)
  • 19 Sep 2024 Armgo Pharma terminates a phase II trial in Polymorphic catecholergic ventricular tachycardia in Netherlands (PO), due to challenges in recruiting patients (NCT05122975)
  • 29 Jan 2024 Efficacy data from a phase I trial in Congenital structural myopathies released by ARMGO Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top